Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MicuRx Pairs US Phase II Trial of Novel Antibiotic with China Test

publication date: Feb 27, 2015
MicuRx Pharma, a US-China company, was granted FDA approval to begin a US Phase II trial of its lead molecule, MRX-I, a novel oral antibiotic for drug-resistant Gram-positive infections. MicuRx, which has already begun a parallel Phase II trial of the antibiotic in China, believes its antibiotic is both safer and more effective than others in the class. Headquartered in the San Francisco area, MicuRx also operates a lab in Shanghai’s Zhangjiang High-Tech Park. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital